Side-by-side · Research reference

OvagenvsPinealon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

ATheoreticalHUMAN-REVIEWED2/42 cited

BHuman-MechanisticAUTO-DRAFTED12/36 cited

Ovagen

Khavinson Bioregulator · Ovarian

OvarianTarget tissue

Di/Tri-peptidePeptide length

AnimalEvidence tier

Oral / SQ · Protocol varies

Pinealon

Pineal-derived · Neuroprotective

5–10 mgPer cycle doseKhavinson 2014

HumanMechanisticKhavinson 2014

HoursHalf-life (est)

SQ or IM · Daily for 10 days · 1-2×/year

01Mechanism of Action

Parameter

Ovagen

Pinealon

Primary target

Ovarian tissue chromatin complexes

Antioxidant defense + neuronal gene expression (proposed)Khavinson 2014

Pathway

Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation

Modulation of antioxidant enzymes (SOD, catalase) + neurotrophic factor expressionKhavinson 2014

Downstream effect

Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration

Reduced oxidative stress in neurons; improved cognitive function in age-related declineKhavinson 2014

Feedback intact?

Presumed physiological — Khavinson peptides described as regulatory, not replacement

—

Origin

Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)

Synthetic 4-AA peptide derived from pineal gland extractKhavinson 2014

Antibody development

—

02Dosage Protocols

Parameter

Ovagen

Pinealon

Standard dose

10–20 mg / day (oral) or 1–2 mg SQ

Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.

5–10 mg / day for 10 daysKhavinson 2014

Frequency

Once daily or cyclical (10–20 days per month)

Cyclical protocols common in Khavinson bioregulator tradition.

Once daily during cycle

Evidence basis

Theoretical / Russian-tradition

Russian clinical trials + in vitroKhavinson 2014

Duration

4–12 weeks per cycle

Khavinson protocols typically 1–3 months; repeat cycles as needed.

10-day cycles, 1–2× per year

Route

Oral (capsule) or subcutaneous

Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.

—

Lower / starter dose

—

2.5 mg / day

Reconstitution

—

Bacteriostatic water

Timing

—

No specific time

Half-life

—

Hours

04Side Effects & Safety

Parameter

Ovagen

Pinealon

Reported adverse events

None documented in indexed literature

—

Theoretical hormonal effects

Ovarian stimulation — monitor for estrogen-sensitive conditions

—

Injection site reaction

Possible mild erythema (SQ route)

Mild irritation

Long-term safety

Unknown — no PubMed-indexed RCTs

Limited Western data

Pregnancy / OB

—

Avoid

Absolute Contraindications

Ovagen

·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
·Pregnancy

Pinealon

·Pregnancy / breastfeeding

Relative Contraindications

Ovagen

·History of estrogen-sensitive tumors (monitor)
·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
·Endometriosis or fibroids (estrogen-responsive conditions)

Pinealon

·Active malignancy (theoretical via gene expression modulation)

05Administration Protocol

Parameter

Ovagen

Pinealon

1. Oral route

Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.

Add 1–2 mL bacteriostatic water to 10 mg vial.

2. Subcutaneous route

1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.

SQ — abdomen preferred.

3. Cyclical protocol

Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.

Daily during cycle, any time.

4. Storage

Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.

Lyophilised: room temp. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

Ovagen

— no documented stacks

Pinealon

+ Epitalon

Moderate

View Epitalon →

Pinealon (neuroprotection) + Epitalon (telomerase activation) form the canonical Khavinson "longevity stack" — both pineal-derived bioregulators with complementary axes. Pinealon supports neuronal antioxidant defense; Epitalon supports telomere maintenance. Anecdotally cycled together 1–2× per year.

Pinealon: 5–10 mg SQ · daily × 10 days
Epitalon: 5–10 mg SQ · daily × 10 days (overlap or alternate)
Primary benefit: Neuroprotection + telomere preservation

Khavinson 2014 Khavinson 2003